AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA ...
With Alberta's population continuing to set records and employment growth leading the country, the province's best employers are investing more than ever in training, skills development and career ...
Q4 2025 Earnings Call January 29, 2026 3:00 AM ESTCompany ParticipantsLine Dovarn - Head of Investor RelationsKlas ...
AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing ...
BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi ...
Real Madrid will be forced to go through the play-offs in the UEFA Champions League (UCL) after a 4-2 defeat at SL Benfica ...
Germain, led by Kylian Mbappe, arrived at St James' Park for a date with a Newcastle side that had not been in the Champions ...
For minor vision loss, simple adjustments like using brighter lights, wearing anti-glare sunglasses and using magnifiers can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results